Acquired <i>CD38</i> gene deletion as a mechanism of tumor antigen escape in multiple myeloma-Reference-Cited by-同舟云学术

Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma

Published:2023-11-30 Issue:23 Volume:7 Page:7235-7238
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Portuguese Andrew J.¹²^ORCID,Fang Min¹²,Tuazon Sherilyn A.¹³,Pont Margot¹⁴,Qu Xiaoyu¹²,Shasha Carolyn¹,Comstock Melissa¹,Lyons Justina¹,Cole Gabriel¹⁴,Newell Evan W.¹²,Glynn Emily²,Soma Lorinda A.¹⁵,Green Damian J.¹²^ORCID

Affiliation:

1. 1Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA

2. 2University of Washington, Department of Medicine, Seattle, WA

3. 3Bristol Myers Squibb, Seattle, WA

4. 4CellPoint Bio, a Galapagos company, Oegstgeest, The Netherlands

5. 5City of Hope Medical Center, Department of Pathology, Duarte, CA

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/7/23/7235/2176350/blooda_adv-2023-011295-main.pdf

Reference13 articles.

1. Sarclisa (isatuximab). Package insert. sanofi-aventis U.S. LLC. 3/2020. Accessed May 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761113s000lbl.pdf.

2. Darzalex (daratumumab). Package insert. Janssen Biotech, Inc. 3/2022. Accessed October 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761036s041lbl.pdf.

3. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy;Gandhi;Leukemia,2019

4. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma;Lin;Am J Clin Pathol,2004

5. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy;Bataille;Haematologica,2006